Romlusevimab |
| カタログ番号GC72460 |
Romlusevimab（BRI-198）は重篤な急性呼吸器症候群コロナウイルス2（SARS-CoV-2）に対するプラスト蛋白質の中和組換えヒトIgG 1モノクローナル抗体である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2509447-08-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Romlusevimab and Amubarvimab bind to distinct epitopes of the SARS-CoV-2 spike protein[1].
Romlusevimab has an additive effect when combined with Amubarvimab[1].
Romlusevimab (10 mg/kg, ip, single) in combination with Amubarvimab protects animals from Omicron infection in a mouse model of SARS-CoV-2 infection[1].
References:
[1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331.
[2]. Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *